All In Biotech

NDA 021112 · Galderma Labs Lp

Tri-Luma

Fluocinolone Acetonide, Hydroquinone, Tretinoin · Topical · Corticosteroid; Melanin Synthesis Inhibitor; Retinoid

Last checked: Nov 20, 2026Latest source record: Jan 20, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Jan 18, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

20 Phase 3, 7 recruiting

FAERS reports

548

47 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 24, 2024.

TRI-LUMA Cream is a combination of fluocinolone acetonide (a corticosteroid), hydroquinone (a melanin synthesis inhibitor), and tretinoin (a retinoid) that is indicated for the short-term treatment of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens. ( 1 ) 1.1 Indication TRI-LUMA Cream is a combination of fluocinolone acetonide (a corticosteroid), hydroquinone (a melanin synthesis inhibitor), and tretinoin (a retinoid) that is indicated for the short-term treatment of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens. 1.2 Limitations of Use TRI-LUMA Cream is NOT indicated for the maintenance treatment of melasma. After achieving control with TRI-LUMA Cream, some patients may be managed with other treatments instead of triple therapy with TRI-LUMA Cream. Melasma usually recurs upon discontinuation of TRI-LUMA Cream. The safety and efficacy of TRI-LUMA Cream in patients of Fitzpatrick Skin Types V and VI have not been studied. Excessive bleaching resulting in undesirable cosmetic effect in patients with darker skin cannot be excluded. The safety and efficacy of TRI-LUMA Cream in the treatment of hyperpigmentation conditions other than melasma of the face have not been studied. Because pregnant and lactating women were excluded from, and women of childbearing potential had to use birth control measures in the clinical trials, the safety and efficacy of TRI-LUMA Cream in pregnant women and nursing mothers have not been established [ see Use in Specific Populations (8.1, 8.3 )].

Mechanism: The mechanism of action of the active ingredients in TRI-LUMA Cream in the treatment of melasma is unknown.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 18, 2002 Original approval · Type 4 - New Combination ReviewLabel
1 products under this application
  • TRI-LUMA · FLUOCINOLONE ACETONIDE 0.01%; HYDROQUINONE 4%; TRETINOIN 0.05% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluocinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • erythema161
  • drug ineffective123
  • skin burning sensation91
  • condition aggravated73
  • skin exfoliation69
  • product use issue54
  • dry skin52
  • pruritus51
  • skin irritation51
  • intentional product use issue50
  • intentional product misuse48
  • skin hyperpigmentation48

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20063
20073
20082
20095
20102
20116
20129
20135
20147
201591
201686
2017110
201822
201948
202047
20214
202218
202319
202415
202519
202625

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 139 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.